<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00189553</url>
  </required_header>
  <id_info>
    <org_study_id>CALYPSO</org_study_id>
    <secondary_id>EudraCT 2004-04456-39</secondary_id>
    <nct_id>NCT00189553</nct_id>
  </id_info>
  <brief_title>Caelyx Plus Carboplatin Versus Paclitaxel Plus Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse</brief_title>
  <acronym>CALYPSO</acronym>
  <official_title>A Multi-National,Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin and Carboplatin Versus Paclitaxel and Carboplatin in Patients With Epithelial Ovarian Cancer in Late Relapse (&gt; 6 Months)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ARCAGY/ GINECO GROUP</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Schering-Plough</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Arbeitsgemeinschaft Gynaekologische Onkologie Austria</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AGO Study Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>ANZGOG</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NCIC Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>NSGO</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>ARCAGY/ GINECO GROUP</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study of the efficacy and safety of Caelyx (pegylated liposomal doxorubicin) in
      combination with carboplatin compared to the standard treatment of paclitaxel and carboplatin
      in patients with epithelial ovarian cancer in late relapse (&gt; 6 months).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main purpose of this research study is to find out if treatment of late relapse of
      ovarian or fallopian tube or primary peritoneal cancer with liposomal doxorubicin (Caelyx)
      combined with carboplatin will control the tumor growth at least as well as standard
      treatment of paclitaxel and carboplatin. And it is hoped that substituting paclitaxel with
      Caelyx in combination with carboplatin will improve the tolerance of the treatment program
      with at least the same efficacy and fewer side effects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival of patients in both study groups</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Qualitative and quantitative toxicities</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">976</enrollment>
  <condition>Ovarian Cancer</condition>
  <condition>Fallopian Tube Cancer</condition>
  <arm_group>
    <arm_group_label>Standard</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paclitaxel-Carboplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Caelyx-Carboplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated liposomal doxorubicin</intervention_name>
    <description>30 mg/m² every 4 weeks during 6 cycles or until progression</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>Caelyx</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>AUC 5 every 3/4 weeks during 6 cycles or until progression</description>
    <arm_group_label>Standard</arm_group_label>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>generic drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>175 mg/m² at day 1 every 3 weeks during 6 cycles or until progression</description>
    <arm_group_label>Standard</arm_group_label>
    <other_name>generic drug</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged &gt; 18

          -  Histologically proven diagnosis of cancer of the ovary, the fallopian tube or
             extra-ovarian papillary serous tumors

          -  Measurable disease (Response Evaluation Criteria in Solid Tumor [RECIST] criteria) or
             cancer antigen (CA) 125 assessable disease (Gynecologic Cancer Intergroup [GCIG]
             criteria) or with histologically proven diagnosis of relapse

          -  Disease in progression &gt; 6 months after a first or second platinum-based line.
             Patients should have previously received a taxane derivative.

          -  ECOG performance status &lt; 2

          -  Life expectancy of at least 12 weeks

          -  Adequate bone marrow, renal, and hepatic function

        Exclusion Criteria:

          -  Ovarian tumors of low malignant potential

          -  Non-epithelial ovarian or mixed epithelial/non-epithelial tumors

          -  Previous radiotherapy

          -  Prior diagnosis of malignancy

          -  Bowel obstruction, sub-occlusive disease, or presence of symptomatic brain metastases

          -  Pre-existing motor or sensory neurologic pathology or symptoms National Cancer
             Institute (NCI) - Common Terminology Criteria for Adverse Events (CTCAE) grade &gt; 1

          -  History of congestive heart failure (New York Heart Association [NYHA] classification
             &gt; 2), history of myocardial infarction within the last 6 months, or history of atrial
             or ventricular arrhythmias

          -  Severe active infection

          -  Severe hypersensitivity to products containing Cremophor EL and/or to compounds
             chemically related to paclitaxel, carboplatin or Caelyx

          -  Fertile women not using adequate contraceptive methods

          -  Pregnant or breast feeding women
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Pujade-Lauraine, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>GINECO GROUP</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Hôtel Dieu</name>
      <address>
        <city>Paris</city>
        <zip>75004</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>January 9, 2014</last_update_submitted>
  <last_update_submitted_qc>January 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Extra-ovarian papillary serous tumors</keyword>
  <keyword>Relapse over 6 months</keyword>
  <keyword>Previously received taxane derivative</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Neoplasms, Glandular and Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

